Which sulfonylurea has been discontinued in tablet form and is available only as an oral suspension for neonatal diabetes mellitus?

Unlock all features

Unlock your full potential with Examzify Plus. Access the complete question bank, personalized progress tracking, and an ad-free experience.

Full question bankExam simulationsFlashcards

From $24.99Unlock all

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

Which sulfonylurea has been discontinued in tablet form and is available only as an oral suspension for neonatal diabetes mellitus?

Glibenclamide (glyburide) is the sulfonylurea linked to treating neonatal diabetes caused by KATP channel mutations. In this condition, the beta-cell KATP channel is overactive, which suppresses insulin release. Glibenclamide binds to the SUR1 subunit of that channel and closes it, allowing insulin to be released even with the genetic defect. The tablet form has been discontinued in some markets, so the drug is now available only as an oral suspension to permit precise dosing in newborns and infants. Other sulfonylureas (gliclazide, glipizide, glimepiride) are mainly used in adults with type 2 diabetes and aren’t the standard treatment for neonatal diabetes, which is why glibenclamide is the correct choice here.

Which sulfonylurea has been discontinued in tablet form and is available only as an oral suspension for neonatal diabetes mellitus?

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Which sulfonylurea has been discontinued in tablet form and is available only as an oral suspension for neonatal diabetes mellitus?

Get the latest from Examzify